Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics

Multiple Sclerosis

Volumn 21, Issue 12, 2015, Pages 1593-1599

  Solomon, Andrew J ^a   Klein, Eran P ^b,c   Corboy, John R ^d,e   Bernat, James L ^f  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

clinical trials; conflict of interest; industry sponsored clinical trials; Multiple sclerosis; professional conduct and ethics

Indexed keywords

ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); COMPENSATION; CONFLICT OF INTEREST; CONTROLLED STUDY; DECISION MAKING; DOCTOR PATIENT RELATION; DRUG INDUSTRY; DRUG RESEARCH; FEMALE; HUMAN; INTERPERSONAL COMMUNICATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROLOGIST; PATIENT ATTITUDE; PATIENT PARTICIPATION; PROFESSIONAL STANDARD; PUBLIC-PRIVATE PARTNERSHIP; RESEARCH ETHICS; UNITED STATES; ECONOMICS; ETHICS; MEDICAL ETHICS; PATIENT SELECTION; PHYSICIAN;

ADULT; CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; DRUG INDUSTRY; ETHICS, MEDICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PATIENT PARTICIPATION; PATIENT SELECTION; PHYSICIANS;

EID: 84985952541     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515569101     Document Type: Article

References (26)

1. Ross JS, Gross CP, Krumholz HM,. Promoting transparency in pharmaceutical industry-sponsored research. Am J Public Health 2012; 102: 72-80.
2. Norris SL, Holmer HK, Ogden LA, et al.,. Conflict of interest disclosures for clinical practice guidelines in the national guideline clearinghouse. PloS one 2012; 7: e47343.
3. Holloway RG, Mooney CJ, Getchius TS, et al.,. Invited article: Conflicts of interest for authors of American Academy of Neurology clinical practice guidelines. Neurology 2008; 71: 57-63.
4. Thompson DF,. Understanding financial conflicts of interest. New Engl J Med 1993; 329: 573-576.
5. GBI Research. Multiple Sclerosis Therapeutics to 2019-Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth. 2013. Bolton, UK: GBI. Available at: www.gbiresearch.com
6. IMS Institute for Health Informatics. The Global Use of Medicines: Outlook Through 2016. 2012. NJ: IMS Inc. Available at: www.imshealth.com
7. Angelos P, Murphy TF, Sampson H, et al.,. Informed consent, capitation, and conflicts of interest in clinical trials: Views from the field. Surgery 2006; 140: 740-748.
8. Raftery J, Bryant J, Powell J, et al.,. Payment to healthcare professionals for patient recruitment to trials: Systematic review and qualitative study. Health Technol Assess 2008; 12: 1-128, iii.
9. Tosounidis TI, Kontakis GM,. Clinical research: The patients' perspectives. Injury 2008; 39: 631-635.
10. Gray SW, Hlubocky FJ, Ratain MJ, et al.,. Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials. J Clin Oncol 2007; 25: 3488-3494.
11. Grady C, Horstmann E, Sussman JS, et al.,. The limits of disclosure: What research subjects want to know about investigator financial interests. J Law Med Ethics 2006; 34: 592-599, 481.
12. Weinfurt KP, Friedman JY, Allsbrook JS, et al.,. Views of potential research participants on financial conflicts of interest: Barriers and opportunities for effective disclosure. J Gen Intern Med 2006; 21: 901-906.
13. Kim SY, Millard RW, Nisbet P, et al.,. Potential research participants' views regarding researcher and institutional financial conflicts of interest. J Med Ethics 2004; 30: 73-79.
14. Hall MA, Friedman JY, King NM, et al.,. Commentary: Per capita payments in clinical trials: reasonable costs versus bounty hunting. Acad Med 2010; 85: 1554-1556.
15. Shuchman M,. Commercializing clinical trials-Risks and benefits of the CRO boom. New Engl J Med 2007; 357: 1365-1368.
16. Fisher JA, Kalbaugh CA,. United States private-sector physicians and pharmaceutical contract research: a qualitative study. PLoS medicine 2012; 9: e1001271.
17. Weinfurt KP, Hall MA, Hardy NC, et al.,. Oversight of financial conflicts of interest in commercially sponsored research in academic and nonacademic settings. J Gen Intern Med 2010; 25: 460-464.
18. Fisher JA,. Practicing research ethics: private-sector physicians & pharmaceutical clinical trials. Soc Sci Med 2008; 66: 2495-2505.
19. Licurse A, Barber E, Joffe S, et al.,. The impact of disclosing financial ties in research and clinical care: a systematic review. Arch Intern Med 2010; 170: 675-682.
20. Weinfurt KP, Hall MA, Dinan MA, et al.,. Effects of disclosing financial interests on attitudes toward clinical research. J Gen Intern Med 2008; 23: 860-866.
21. Hampson LA, Agrawal M, Joffe S, et al.,. Patients' views on financial conflicts of interest in cancer research trials. New Engl J Med 2006; 355: 2330-2337.
22. Raftery J, Kerr C, Hawker S, et al.,. Paying clinicians to join clinical trials: a review of guidelines and interview study of trialists. Trials 2009; 10: 15.
23. Rochon PA, Hoey J, Chan AW, et al.,. Financial conflicts of interest checklist 2010 for clinical research studies. Open Med 2010; 4: e69-91.
24. Weinfurt KP, Hall MA, King NM, et al.,. Dis-closure of financial relationships to participants in clinical research. New Engl J Med 2009; 361: 916-921.
25. Ferris LE, Naylor CD,. Physician remuneration in industry-sponsored clinical trials: the case for standardized clinical trial budgets. Can Med Assoc J 2004; 171: 883-886.
26. Morin K, Rakatansky H, Riddick FA Jr, et al.,. Managing conflicts of interest in the conduct of clinical trials. JAMA 2002; 287: 78-84.